A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Garrigós L, Ruiz-Borrego M, Pérez-García JM, Guerrero-Zotano A, Cortés-Salgado A, Kuemmel S, Colleoni M, Reboredo-Rendo C, Bermejo B, Blancas I, Gavila J, Fabi A, Morales C, Stradella A, Carañana V, Martínez-de Dueñas E, Albacar C, Ballesteros-Cidras O, Martrat G, Iacobucci S, Boix O, Berenguer-Molins P, Alcalá-López D, Cortés J, Llombart-Cussac A, PHERGain-2 investigators.

Open source

DOI: 10.1016/j.annonc.2026.01.013
Published: 2026-05-06
Container: Ann Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.01.013,
  title = {A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.},
  author = {Garrigós L and  Ruiz-Borrego M and  Pérez-García JM and  Guerrero-Zotano A and  Cortés-Salgado A and  Kuemmel S and  Colleoni M and  Reboredo-Rendo C and  Bermejo B and  Blancas I and  Gavila J and  Fabi A and  Morales C and  Stradella A and  Carañana V and  Martínez-de Dueñas E and  Albacar C and  Ballesteros-Cidras O and  Martrat G and  Iacobucci S and  Boix O and  Berenguer-Molins P and  Alcalá-López D and  Cortés J and  Llombart-Cussac A and  PHERGain-2 investigators.},
  year = {2026},
  journal = {Ann Oncol},
  doi = {10.1016/j.annonc.2026.01.013},
  url = {https://doi.org/10.1016/j.annonc.2026.01.013}
}

RIS

TY  - JOUR
TI  - A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
AU  - Garrigós L
AU  -  Ruiz-Borrego M
AU  -  Pérez-García JM
AU  -  Guerrero-Zotano A
AU  -  Cortés-Salgado A
AU  -  Kuemmel S
AU  -  Colleoni M
AU  -  Reboredo-Rendo C
AU  -  Bermejo B
AU  -  Blancas I
AU  -  Gavila J
AU  -  Fabi A
AU  -  Morales C
AU  -  Stradella A
AU  -  Carañana V
AU  -  Martínez-de Dueñas E
AU  -  Albacar C
AU  -  Ballesteros-Cidras O
AU  -  Martrat G
AU  -  Iacobucci S
AU  -  Boix O
AU  -  Berenguer-Molins P
AU  -  Alcalá-López D
AU  -  Cortés J
AU  -  Llombart-Cussac A
AU  -  PHERGain-2 investigators.
PY  - 2026
JO  - Ann Oncol
DO  - 10.1016/j.annonc.2026.01.013
UR  - https://doi.org/10.1016/j.annonc.2026.01.013
ER  -

APA

L, G., M, R., JM, P., A, G., A, C., S, K., M, C., C, R., B, B., I, B., J, G., A, F., C, M., A, S., V, C., E, M. D., C, A., O, B., G, M., S, I., O, B., P, B., D, A., J, C., A, L., & investigators., P. (2026). A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.. Ann Oncol. https://doi.org/10.1016/j.annonc.2026.01.013

Source records

europe-pmc · retrieved 2026-09-25T09:31:07.638Z